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Abstract
Background—A decade after the rollout of antiretroviral therapy (ART) in sub-Saharan Africa, 
the effects of this structural change on social aspects of HIV such as rates of HIV disclosure to 
partners remain largely unmeasured. We evaluated whether the introduction of ART was 
associated with disclosure of HIV diagnosis to spouses in Rakai, Uganda, using longitudinal, 
population-based data.
Methods—We identified individuals in marital/cohabitating unions who were newly diagnosed 
with HIV in Rakai Community Cohort Study (RCCS) surveys between 2000 and 2008, where 
antiretroviral therapy (ART) was introduced in mid-2004. Using discrete-time survival analysis, 
we assessed the hazard of self-reported HIV disclosure to spouse after diagnosis pre- and post-
ART rollout, adjusting for individual and union characteristics. Disclosure in the ART period was 
further stratified by ART initiation.
Results—The analysis included 557 married adults, 264 of whom were diagnosed with HIV 
before ART was available (2000-2004) and 293 diagnosed after ART was introduced 
(2005-2008). The cumulative incidence of self-reported disclosure was 75.2% in the post-ART 
period, compared to 58.3% before ART availability (p<0.001, adjusted hazard 1.46 [95% CI 1.16, 
1.83]). In the post-ART period, observed disclosure rates were 39% (72/184) among those not in 
HIV care, 65% (82/126) among those in pre-ART care, and 85% (64/75) among persons on ART 
(p<0.001).
Conclusions—Treatment availability and use, especially ART initiation, was associated with 
increased self-disclosure of HIV diagnosis to partners. ART access may facilitate the prevention 
of transmission to uninfected partners and linkage to treatment for infected couples.
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INTRODUCTION
Disclosure of positive HIV serostatus to spouses and other sexual partners is an important 
step in the pathway of transmission prevention through sexual risk reduction and uptake of 
prevention, treatment, and support services. However, individuals consider potential positive 
and negative consequences of sharing their positive HIV results with their spouse. 
Disclosure might stress or lead to the dissolution of the relationship if the partner responds 
with rejection, blame, or anger, though most studies have found that severe negative 
consequences such as violence and separation are relatively uncommon (1-3). Before 
communities in sub-Saharan Africa had access to ART, individual benefits of disclosure to 
one's spouse centered on emotional and instrumental support (4;5), improved mental health 
(2), ability to initiate safer sex practices within the relationship (2), and spousal support to 
access available medical care and short course ART regimens to prevent mother to child 
transmission (PMTCT) (4;6). Access to antiretroviral therapy (ART) in low and middle 
income countries increased 16-fold since 2003 (7). This structural change may have 
motivated disclosure among people with HIV directly—in order to openly seek ART and to 
enable one's potentially infected partners and children to benefit from treatment—and 
indirectly, by changing attitudes and reducing HIV-related stigma and discrimination (8).
Prior to ART availability, prospective studies found that less than half of HIV-infected 
women in antenatal care had disclosed their status to their sexual partner within 2 years after 
diagnosis in Cote d'Ivoire (9) and within 4 years in Tanzania (6). A systematic review found 
that on average, 49% of HIV-infected African adults reported disclosing their infection to 
their sexual partner, compared to 79% in high income countries (10). The lack of affordable 
treatment at the time may have contributed to the lower disclosure rates reported in Africa.
In contrast, several cross-sectional studies conducted after ART rollout reported disclosure 
rates to sexual partners of 62% to 79% in diverse populations attending HIV care and 
support groups in Uganda, Kenya and South Africa (2;11-13). However, these estimates are 
limited by their cross-sectional design, lack of data on pre-ART disclosure rates, variable 
recall time since HIV diagnosis, and participant self-selection into these programs. 
Longitudinal data on the effect of ART availability and initiation on HIV disclosure in a 
general African population remain limited. In this analysis, we use longitudinal population-
based data collected between 2000 and 2008 to evaluate the association between ART 
availability and disclosure of newly diagnosed HIV infection to spouses by men and women 
in stable unions in rural Rakai district, Uganda. ART was introduced in this population in 
mid-2004, and was widely available through fixed and mobile clinics by 2005.
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METHODS
Study Setting and Population
Since 1994, the Rakai Health Sciences Program (RHSP) has enrolled all consenting 
residents aged 15-49 in 50 villages in Rakai District, southwestern Uganda, into the Rakai 
Community Cohort Study (RCCS) (14). The RCCS administers behavioral questionnaires 
and collects venous blood for HIV-1 testing from participants approximately every 18 
months. Approximately 94% of residents present in the community agree to participate in 
each survey round, and approximately 95% of participants provide a serologic sample for 
HIV testing. Between 2000 and 2008, participants were offered their HIV results through 
free post-test counseling, provided by trained RHSP counselors in participants’ homes or 
other venues of choice (15;16). Although RHSP promotes receipt of results and counseling, 
testing and receipt were voluntary as per contemporaneous Ugandan Ministry of Health 
guidelines. Participants could choose to receive their HIV results individually or with their 
partner, and the protocol for returning new seropositive test results did not change over the 
study period.
In June 2004, ART first became available in Rakai, delivered by RHSP with funding from 
the USA President's Emergency Plan for AIDS Relief (PEPFAR). ART was initiated for 
those with a CD4 cell count <250/mm3 or WHO stage IV disease. The program continued to 
provide cotrimoxazole prophylaxis, general healthcare, and other supportive services for 
those who did not meet ART eligibility criteria. With rapid scale-up and outreach, by 2005, 
less than one year after ART services were introduced, 87% of the community reported 
knowing where to access treatment.
The analytic sample included all RCCS participants in marital or consensual unions who 
received a new diagnosis of HIV infection from 2000 to 2006 (survey rounds 7-11). The 
study followed these participants and measured disclosure through 2008 (survey round 12). 
We included a participant regardless of whether his or her spouse participated in the survey.
Measurements
Participants who seroconverted between survey rounds or who tested positive at their first 
HIV test were classified as newly diagnosed once they reported receiving their HIV results. 
Participants’ sera were tested for HIV-1 at each survey round with two enzyme 
immunoassay (EIA) tests (Vironostika HIV-1, Organon Teknike, Charlotte, NC, USA and 
Cambridge Biotech, Worcester, MA, USA) and confirmed positive or discordant EIA results 
by Western blot (HIV-1 Western Blot, Bio-Merieux-Vitek, St. Louis, MO, USA).
At each survey round, participants were interviewed regarding disclosure of HIV results to 
their spouse in the period between survey rounds. The disclosure outcome combined the 
response categories of disclosure through couples counseling and self-reported individual 
disclosure. For this analysis, we assessed cumulative rates of disclosure within up to three 
survey intervals following diagnosis (encompassing approximately 5 years). All 
observations were administratively censored after 2008.
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ART availability, the primary predictor, is time-varying based on the year of the survey 
round. We defined the pre-ART period as the three survey rounds from 2000-mid-2004 and 
the post-ART period as the two survey rounds from mid-2004-January 2008 (Figure 1). As 
an external variable, ART availability was defined uniformly for all participants and was not 
dependent on self-use of ART. We compared these rounds, which were most proximal to 
ART rollout, to minimize the influence of secular changes that could affect disclosure. In 
addition, ART availability at diagnosis, a fixed variable, was used to stratify and compare 
the cumulative disclosure estimates.
Individual-level and union-level covariates were reported in the RCCS interview; the 
variables most likely to change due to disclosure were drawn from the interview prior to the 
visit (lagged) in which the disclosure outcome was measured. The individual characteristics 
included gender, age category, education level, wealth, formal labor force participation, 
religion, extramarital sex partners (lagged), alcohol consumption, attitude toward intimate 
partner violence (IPV), AIDS symptoms (lagged), and being bedridden within 30 days prior 
to the interview (lagged). Household wealth was based on an index of the quality of the roof, 
walls, and floor materials of the home, grouped into tertiles. Respondents with clerical, 
teaching, government, service industry, or trading/vending jobs were classified as part of the 
formal labor force. AIDS symptoms were substantial weight loss, diarrhea for longer than 
one month, fever for longer than one month, Kaposi sarcoma, herpes zoster, oral thrush, or 
tuberculosis.
Union-level covariates included polygamy, union type (married vs consensual), spousal age 
difference, union duration, and the report of verbal or physical abuse by spouse (females) or 
toward spouse (males). For males in polygamous unions, all union-level covariates refer to 
the wife with whom they reported the most recent sexual activity (self-reported disclosure to 
multiple wives was consistent in 79% of observations).
We linked RHSP HIV treatment program data to the RCCS community data by unique study 
identification number to assess whether a participant had accessed pre-ART care or initiated 
ART, as a secondary analysis.
Analysis
Means and proportions were calculated and t-tests or Chi-square tests were used to compare 
differences between individuals newly diagnosed with HIV prior to ART availability and 
those diagnosed after ART became available.
We use a discrete-time proportional hazards model (17). The hazard can be interpreted as 
the probability of disclosing one's HIV results to one's spouse in a given inter-survey 
interval, conditional on not having disclosed by the start of that interval. A generalized 
linear regression model with a complementary log-log specification was used to assess the 
association between ART availability and disclosure.
We fit the baseline discrete-time survival model with follow-up interval (time), stratified by 
ART availability at diagnosis, to estimate total and gender-stratified cumulative disclosure 
incidence for the pre-ART and post-ART periods. Bivariate models were fitted with each 
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potential predictor and time to estimate unadjusted hazards of disclosure. For the 
multivariable model, in addition to time-varying ART availability and the gender of the 
disclosing partner, we included and all predictors with unadjusted hazards with p-values < 
0.10. We tested for a multiplicative interaction between gender and ART availability in the 
multivariable model. A secondary analysis, limited to the post-ART period, assessed the 
association between use of HIV treatment and disclosure —one pathway through which 
community-level ART availability could affect disclosure—by Chi-square test and a 
multivariable proportional hazard model. All analyses used Stata versions 9.1 or 12.0 (Stata 
Corp., College Station, TX).
Ethics statement
The AIDS Research Subcommittee of the Uganda National Council for Science and 
Technology, the Uganda Virus Research Institute, Science and Ethics Committee, and the 
Western Institutional Review Board (Olympia, WA) reviewed and approved this secondary 
data analysis and the RCCS and clinic data collection. The study team obtained written 
informed consent at enrollment and at each annual follow-up, and participants could opt-out 
of any part of the study. Patients attending RHSP care and treatment centers provided 
written informed consent to have their clinical data base linked to RCCS data. Personal 
identifiers were stripped from the databases prior to our use.
RESULTS
From 2000 to 2006, 557 RCCS participants in marital unions were newly diagnosed with 
HIV, contributing 725 person-intervals of observation. More than three quarters of 
individuals contributed only one interval of observation because they disclosed their 
diagnosis in the same interval in which they received results (n=317), didn't participate in 
the subsequent survey round (n=66), or were administratively censored after survey round 
12 (n=51). Two hundred sixty-four (47%) participants were diagnosed before ART became 
available and 293 (53%) after it became available. Missingness was less than 3% for any 
variable, and multivariable analysis was limited to the 703 of 725 (97%) person intervals 
with non-missing data. Individuals diagnosed in the pre-ART years who had not yet 
disclosed by ART introduction contributed person-time both in the pre- and post-ART 
periods.
Participants diagnosed in the pre-ART period were comparable on most characteristics to 
their counterparts diagnosed after ART was available (Table 1). However, participants 
diagnosed in the post-ART period were significantly more likely to be female and to be in a 
consensual union compared to formal marriage. A minority of the population reported 
serious illness during the study visit when they received their results; 9% reported AIDS-
associated symptoms and 11% reported being bedridden in the past month. Receipt of 
couples counseling among the newly diagnosed was similarly low (10%) between the two 
periods.
By the end of the second interval after diagnosis, disclosure increased from an estimated 
58% in the pre-ART period to 75% in the post-ART period (p <0.001) (Figure 2). Stratified 
by gender, disclosure increased after the ART rollout among both men (63% pre-ART vs. 
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78% post-ART) and women (55% pre-ART vs. 73% post-ART). The rate of disclosure was 
highest within the first follow-up interval after HIV diagnosis (Figure 2). 127 of the 139 
disclosures in the pre-ART period (91.4%) and 190 of the 198 disclosure in the post-ART 
period (95.9%) occurred within the first follow-up interval.
The adjusted hazard of disclosure was 46% higher in the post-ART period relative to the 
pre-ART period (adjHR: 1.46 95% CI 1.16-1.83, p<0.001) (Table 2). Women were 20 
percent less likely to disclose their HIV diagnosis to their partners than were men over the 
entire period of follow-up (adjHR 0.79, 95% CI 0.62-1.00, p=0.046), and the effect of 
gender on disclosure was not statistically significantly modified by ART availability 
(interaction term not included in the final model due to lack of statistical significance).
Over the entire period, the hazard of disclosing to one's spouse was significantly increased 
with longer duration of the relationship (adjHR 1.30, 95% CI 1.13-1.49) and the presence of 
AIDS-associated symptoms prior to disclosure (adjHR 1.56, 95% CI 1.09-2.24). The 
likelihood of disclosure was lower among adults who reported alcohol use (adjHR 0.73, 
95% CI 0.57-0.93) and with higher levels of education (adjHR 0.81, 95% CI 0.72-0.91). 
Other covariates were not significantly associated with disclosure.
In the post-ART period, disclosure to a spouse was strongly associated with utilization of 
HIV treatment services. Among the 385 person-intervals observed after ART availability, 
disclosure rates were 39% (72/184) among those who had not sought HIV care, 65% 
(82/126) among those on pre-ART care, and 85% (64/75) among those on ART (p<0.001) 
(Figure 3). In a discrete time survival analysis limited to the post-ART period, the adjusted 
hazard of disclosure was 3.26 (95% CI 2.16-4.92; p<0.001) when participants were on ART 
and 2.09 (95% CI 1.48-2.95; p<0.001) when participants were enrolled in pre-ART care, 
compared to those not in care.
DISCUSSION
We found a significant increase in disclosure of HIV infection to a spouse (from 63% to 
78% among men, and from 55% to 73% among women) after the introduction of an ART 
program in a rural African community. To our knowledge, these are the first disclosure 
estimates reported from a general population in sub-Saharan Africa that directly quantify the 
change in disclosure after ART rollout.
Additionally, in the ART era, enrollment in ART or pre-ART care was strongly associated 
with disclosure to a spouse. Operations research in Rakai documented the desire to access 
ART as a motivating factor to disclose one's HIV diagnosis to one's spouse (Neema 
Nakyanjo, personal communication, 2006), a finding also reported in another study of 
disclosure in Uganda (2). Self-interest in preserving one's health and concerns for one's 
spouse's health or HIV status could thus outweigh fears about disclosure. This is consistent 
with studies that have found disclosure to be positively associated with ART uptake (18-20) 
and adherence (21;22), though in some contexts, preserving one's health through ART use 
has been reported as a strategy to avoid disclosure (23). Initiating treatment without 
disclosing to a spouse could lead to unintended disclosure because it would be difficult to 
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conceal treatment, including frequent clinical visits, from a cohabitating partner. More 
positively, a study in Uganda found that both men and women used their treatment as an 
opportunity for indirect (but intended) disclosure, by leaving their medications or health 
records in a place where their spouse would see them (2). Models of HIV testing and/or care 
can themselves facilitate disclosure, notably couples counseling and family-centered clinical 
care. The RHSP clinical program recommends and supports disclosure, and patients are 
encouraged to select a treatment companion to support their drug adherence. Spouses served 
as treatment companions for 71% of married men and 49% of married women on ART. 
Therefore, the need for treatment support may motivate the disclosure of HIV status to the 
spouse, particularly among men, either before or after initiating ART.
Knowledge of ART availability and its effectiveness for improved survival, which was high 
in this population, might have also contributed to higher rates of disclosure by reducing 
stigma. Though this pathway was not evaluated in our study, its plausibility is supported by 
studies that have found lower levels of self-reported stigmatizing attitudes or behaviors after 
ART rollout (24), in areas with greater ART access compared to those without (25;26) and 
among people with knowledge of how to access ART (25;27).
These findings provide insight into predictors of disclosure in a general population with 
access to HIV care. The lower probability of disclosure by HIV-infected women compared 
to men throughout the period of observation suggests that despite the availability of 
treatment, women may continue to anticipate more negative consequences of disclosure, 
which numerous studies have demonstrated as the most significant barrier to disclosure for 
women in sub-Saharan Africa (3;4;6;28). Our finding that disclosure is more likely in longer 
established relationships is consistent with previous findings in Tanzania (6), although the 
inverse association with education differed from a study in Nigeria (29). The reasons for the 
lower rates of disclosure among those with higher levels of education are unclear, but it is 
plausible that status loss associated with stigma is more acute for those with a higher social 
standing.
Despite relatively high disclosure among people with HIV in Rakai, a substantial subset of 
adults diagnosed with HIV had not shared this knowledge with their partner. While we hope 
that intensive programs for serodiscordant couples, disclosure support, and the reduction of 
violence against women launched in Rakai since this study period have further increased 
disclosure rates, HIV programs must continue to develop innovative models to facilitate safe 
disclosure. Our findings suggest that men and women in newer relationships may require 
additional support around disclosure, and that the integration of motivational interviewing 
and other interventions to address high-risk drinking within HIV testing or care and support 
programs may also benefit disclosure.
Several factors limit the conclusions that can be drawn from this study. First, it is possible 
that other factors coincided with ART introduction and influenced disclosure, although 
RHSP was the main provider of HIV counseling, testing, and other preventive services in all 
RCCS villages during the period of analysis, and did not implement any substantial changes 
in these interventions in this time period. The time period of observation was purposively 
restricted to three survey rounds pre-ART and two rounds post-ART to further reduce the 
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chance of secular changes. Second, the non-informative censoring assumption underlying 
the proportional hazards survival method could be violated if out-migration or marital 
dissolution was associated with disclosure. Third, this analysis does not account for the HIV 
status and disclosure behavior of the spouse, but we favored individual-level over couple-
level analysis to avoid exclusion of couples where one partner was unavailable during a 
survey round. Finally, self-reported disclosure outcomes should be interpreted with caution, 
since a perception that non-disclosure would be negatively judged by the interviewer could 
introduce social desirability bias and inflate self-reports of disclosure. Interviewers were 
unaware of respondents’ HIV status, and such bias is unlikely to differ between the two 
periods, however. Our community cohort design reduces the self selection that can occur in 
samples drawn from clinical, VCT, or couples counseling programs, and increases the 
generalizability of our findings. Cohort and HIV testing procedures and the characteristics of 
newly diagnosed HIV+ participants were comparable before and after ART introduction, so 
it is unlikely that the distribution of unobserved confounders would differ between the 
periods and affect results. The longitudinal design enabled us to observe individuals from 
the time they were diagnosed until the time they disclosed their results or were censored, 
reducing potential prevalence/incidence bias and recall bias. Time-varying measurement of 
predictors allowed us to account for changes in exposure over time. Since many of the 
studies that prospectively measured HIV disclosure were limited to women, our study adds a 
direct gender comparison of disclosure rates.
In summary, we demonstrated that ART availability was associated with disclosure of HIV 
infection to a spouse in a setting where free HIV testing and counseling are available. 
Disclosure within couples, in turn, facilitates linking infected partners to care, accessing 
PMTCT services, and preventing sexual transmission to uninfected partners through sexual 
risk reduction and treatment-centered prevention approaches. As the knowledge of HIV 
status in sub-Saharan Africa increases rapidly with expanded access to testing and 
counseling (7), the availability of ART in communities and supportive models of care will 
continue to be important factors to increase disclosure and facilitate HIV transmission 
prevention.
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Figure 1. Timeline of ART rollout relative to RCCS survey rounds (R7-R12) in Rakai, Uganda, 
2000-2008
Legend: ART was first provided in Rakai Uganda clinics in June 2004, toward the end of 
Round 10 of the Rakai Community Cohort Survey (RCCS). Rounds 8-10 are thus classified 
as pre-ART rounds, because the majority of the recall period for Round 10 respondents 
occurred before ART access, and diffusion of knowledge about ART availability likely took 
several months to reach the 87% knowledge of ART access reported by community 
members in RCCS Round 11.
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Figure 2. Cumulative incidence of HIV serostatus disclosure among HIV-infected adults in stable 
unions in Rakai, Uganda, by ART availability at the time of diagnosis
Legend: By the second survey round after diagnosis, 75% of adults reported disclosure to 
their spouse in the post-ART period, compared to 58% in the pre-ART period.
HABERLEN et al. Page 12
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. Disclosure of HIV diagnosis to spouse by HIV care status, among HIV-infected adults 
in stable unions in Rakai, Uganda in the post-ART period (2004-2008)
Legend: Abbreviations: ART=antiretroviral therapy, CI=confidence interval.(a) Limited to 
the first survey intervals after HIV diagnosis. Regression model adjusts for gender, 
education, polygamous union, union duration, alcohol, verbal abuse by husband, and HIV 
symptoms. **p<0.001
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Table 1
Baseline descriptive characteristics of 557a adults in married or consensual unions receiving HIV diagnosis 
before and after ART was available in Rakai, Uganda, 2000-2008
Diagnosed with HIV pre-ART (n=264) Diagnosed with HIV post-ART (n=293)
n proportion n proportion p-value
Sex
    Female 144 0.55 187 0.64 0.03
    Male 120 0.45 106 0.36
Mean age (SD) 30.2yrs (0.4yrs) 30.8yrs (0.4yrs) 0.31
Educationb
    None 21 0.08 22 0.08 0.25
    P1-P4 72 0.27 72 0.25
    P5-P7 109 0.41 130 0.44
    S1-S4 40 0.15 56 0.19
    >S4 22 0.08 13 0.04
Wealth
    Low 120 0.45 104 0.35 0.05
    Medium 77 0.29 98 0.33
    High 67 0.25 91 0.31
Labor force participation 96 0.36 85 0.29 0.06
Union type
    Married 180 0.68 148 0.51 <0.001
    Consensual 84 0.32 145 0.49
Union duration (yrs)
    0-4 118 0.45 114 0.39 0.27
    5-9 79 0.30 90 0.31
    >=10 66 0.25 89 0.30
Extramarital partner in past year 61 0.23 67 0.24 0.77
HIV symptoms in past year 21 0.08 26 0.09 0.60
Bedridden (last month) 30 0.12 34 0.12 0.81
HIV test results delivery
    Couples 29 0.11 24 0.08 0.26
    Individuals 235 0.89 269 0.92
Accepting Attitude toward IPV 167 0.78 211 0.83 0.17
a57 respondents were missing data on IPV attitudes, 21 participants were missing data on HIV symptoms and being bedridden; 16 participants 
were missing data on extramarital partner, and 1 participant was missing data on union duration.
b
P1-P7 are primary school grades 1-7; S1-S4 are secondary school grades 1-4 (equivalent to US high school); Beyond S4 includes Advanced level 
(S5-S6), diploma programs, and technical school or university.
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Table 2
Relative hazards of HIV serostatus disclosure to spouse among men and women in married or consensual 
unions, by ART availability and other predictors, Rakai, Uganda, 2000-2008
Unadjusted HR 95% CI Adjusted HR 95% CI
Period of ART availability 1.56*** (1.26,1.94) 1.46*** (1.16,1.83)
DEMOGRAPHIC CHARACTERISTICS
Female 0.89 (0.72,1.10) 0.79* (0.62,1.00)
Age category 1.06 (0.96,1.17)
Education level 0.83** (0.74,0.92) 0.81*** (0.72,0.91)
Wealth tertile 0.96 (0.85,1.09)
Labor force participation 0.85 (0.68,1.07)
Religion
    Muslim 1.00 (REF)
    Christian/Other 1.07 (0.79,1.46)
UNION CHARACTERISTICS
In polygamous union 0.80 (0.63,1.03) 0.86 (0.66,1.11)
Union type
    Marital union 1.00 (REF)
    Consensual union 0.85 (0.68,1.06)
Union duration (category) 1.27*** (1.11,1.44) 1.30*** (1.13,1.49)
Spousal age difference (category) 0.98 (0.87,1.11)
BEHAVIORAL
Extramarital partner 0.89 (0.66,1.20)
Alcohol in past 30 days 0.72** (0.58,0.89) 0.73* (0.57,0.93)
Accepting attitude of IPV 1.10 (0.82,1.48)
Verbal abuse by husband 0.82 (0.65,1.02) 0.90 (0.71,1.14)
Physical abuse by husband 0.89 (0.68,1.15)
HIV MORBIDITY
Any AIDS symptom 1.64** (1.16,2.32) 1.56* (1.09,2.24)
Bedridden 0.99 (0.71,1.37)
HR=hazard ratio, p-values
*
<0.05
**
<0.01
***
<0.001
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